Literature DB >> 10233979

Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8.

P Kellam1, D Bourboulia, N Dupin, C Shotton, C Fisher, S Talbot, C Boshoff, R A Weiss.   

Abstract

Human herpesvirus 8 (HHV-8; also designated Kaposi's sarcoma-associated herpesvirus) is the likely etiological agent of Kaposi's sarcoma (KS). HHV-8 encodes a latent nuclear antigen (LNA) which is the product of the viral gene orf 73. LNA is recognized by most infected patient sera and is the basis of current immunofluorescence assays used in epidemiological studies of HHV-8 infection. Here we describe the characterization of four monoclonal antibodies raised to the C-terminal third of LNA-glutathione S-transferase fusion proteins. These monoclonal antibodies recognized discrete linear epitopes within the C terminus and repetitive region of LNA, detected antigen in primary effusion lymphoma (PEL) cells, and precipitated a 220- to 230-kDa protein doublet corresponding to LNA from HHV-8-infected PEL cell lines. In situ immunocytochemistry of KS lesions with these antibodies show that LNA is extensively expressed in KS spindle cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233979      PMCID: PMC112561          DOI: 10.1128/JVI.73.6.5149-5155.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen.

Authors:  L Rainbow; G M Platt; G R Simpson; R Sarid; S J Gao; H Stoiber; C S Herrington; P S Moore; T F Schulz
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.

Authors:  P S Moore; C Boshoff; R A Weiss; Y Chang
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

3.  Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; D R Hoover; T J Spira; C R Rinaldo; A Saah; J Phair; R Detels; P Parry; Y Chang; P S Moore
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

4.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

5.  Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen.

Authors:  G R Simpson; T F Schulz; D Whitby; P M Cook; C Boshoff; L Rainbow; M R Howard; S J Gao; R A Bohenzky; P Simmonds; C Lee; A de Ruiter; A Hatzakis; R S Tedder; I V Weller; R A Weiss; P S Moore
Journal:  Lancet       Date:  1996-10-26       Impact factor: 79.321

6.  Open reading frame 26 of human herpesvirus 8 encodes a tetradecanoyl phorbol acetate- and butyrate-inducible 32-kilodalton protein expressed in a body cavity-based lymphoma cell line.

Authors:  E O'Neill; J L Douglas; M L Chien; J V Garcia
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species.

Authors:  T M Rose; K B Strand; E R Schultz; G Schaefer; G W Rankin; M E Thouless; C C Tsai; M L Bosch
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; M Li; W Zheng; C Parravicini; J Ziegler; R Newton; C R Rinaldo; A Saah; J Phair; R Detels; Y Chang; P S Moore
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

9.  The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women.

Authors:  D H Kedes; D Ganem; N Ameli; P Bacchetti; R Greenblatt
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

10.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Authors:  L Arvanitakis; E A Mesri; R G Nador; J W Said; A S Asch; D M Knowles; E Cesarman
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

View more
  31 in total

1.  Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein.

Authors:  W Low; M Harries; H Ye; M Q Du; C Boshoff; M Collins
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies.

Authors:  D R Schwam; R L Luciano; S S Mahajan; L Wong; A C Wilson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures.

Authors:  D M Ciufo; J S Cannon; L J Poole; F Y Wu; P Murray; R F Ambinder; G S Hayward
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 4.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

5.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  C Parravicini; B Chandran; M Corbellino; E Berti; M Paulli; P S Moore; Y Chang
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 6.  Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.

Authors:  C Boshoff; R A Weiss
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  Detection of KSHV in transbronchial biopsies in patients with Kaposi sarcoma.

Authors:  Michael W Si; Jaishree Jagirdar; Yan-Jin Zhang; Shou-Jiang Gao; I-Tien Yeh
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-03

8.  Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Chuang-Jiun Chiou; Lynn J Poole; Peter S Kim; Dolores M Ciufo; Jennifer S Cannon; Colette M ap Rhys; Donald J Alcendor; Jian-Chao Zong; Richard F Ambinder; Gary S Hayward
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Complex alternative cytoplasmic protein isoforms of the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 generated through noncanonical translation initiation.

Authors:  Tuna Toptan; Lidia Fonseca; Hyun Jin Kwun; Yuan Chang; Patrick S Moore
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus.

Authors:  Costin Tomescu; Wai K Law; Dean H Kedes
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.